암 바이오마커 시장 : 바이오마커 유형별, 암 유형별, 주요 지역별 - 업계 동향과 세계 예측(- 2035년)

Cancer Biomarkers Market by Type of Biomarker, Type of Cancer and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,754,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,851,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,918,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,333,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 암 바이오마커 시장 규모는 2035년까지 예측 기간 동안 5%의 연평균 복합 성장률(CAGR)로 확대되어 현재 286억 달러에서 2035년까지 467억 달러로 성장할 것으로 예상됩니다.

체크포인트 억제제 등 일부 면역치료제의 임상적 성공은 여러 고형암에서 이미 입증된 바 있습니다. 그러나 특정 암종에 걸린 다양한 환자들을 치료할 수 있는 치료법 평가에 대한 미충족 수요는 여전히 존재합니다. 같은 암(같은 병기)을 앓고 있는 환자라 할지라도 분자 프로파일이 다르고, 권장되는 약물/치료법에 대한 반응이 다를 수 있기 때문입니다. 환자에게 더 나은 결과를 얻기 위해서는 신뢰할 수 있는 암 바이오마커를 식별하는 것이 중요합니다. 바이오마커는 개별 종양의 분자적 특징에 대한 귀중한 정보를 제공하고, 임상의가 각 환자의 고유한 프로파일에 맞는 치료 전략을 수립할 수 있게 해줍니다.

암 바이오마커는 스크리닝, 암 분류, 위험도 평가, 종양 부하 판단, 치료 맞춤화 및 모니터링, 예후 예측 등 암 치료의 다양한 측면에서 활용될 수 있는 잠재력을 가지고 있으며, 그 미래는 매우 유망합니다. 또한, 유전체, 단백질체학, 대사체학, 마이크로 RNomic 프로파일링, 비교유전체하이브리데이션(CGH), 단일염기다형성(SNP) 분석, 하이스루풋스크리닝(HTS), 차세대염기서열분석(NGS) 등의 기술이 발전하면서 새로운 종양 시그니처를 발견할 수 있는 길이 열리고 있습니다. 새로운 종양 시그니처를 발견할 수 있는 길이 열리고 있습니다. 또한, 강력한 단백질체학 및 유전체 기술의 출현과 순환종양세포(CTC), 암 줄기세포 특이적 마커 및 세포가 없는 순환종양 DNA(ctDNA) 분석이 결합하여 암의 조기 발견, 병의 진행 모니터링 및 적절한 치료법 선택을 위한 보다 민감하고 특이적인 바이오마커 개발에 기여하고 있습니다. 기술 혁신의 빠른 속도와 개인화 접근법에 대한 관심이 높아짐에 따라 암 바이오마커 시장은 당분간 주목할 만한 성장을 이룰 것으로 예상됩니다.

현재 시장에는 약 100개의 새로운 암 바이오마커 솔루션이 출시되어 있으며, 이들 솔루션의 대부분은 암 바이오마커를 평가하기 위해 차세대 시퀀싱을 사용하고 있습니다.

이 업계의 이해관계자들은 다양한 용도의 신규 암 바이오마커 솔루션을 제공하고 있으며, 이들 솔루션의 70% 이상이 MSI/MMR 평가를 지원하고 있습니다. 암 바이오마커 검사 솔루션 제공업체의 현재 시장 환경은 단편화되어 있으며, 신규 진출기업과 기존 기업 모두 존재합니다. 현재 새로운 암 바이오마커를 연구하기 위해 다양한 지역에서 약 685건의 임상시험(75,000명 이상의 환자 등록)이 진행 중입니다. 암 바이오마커 분야에서는 다양한 연구자들에 의해 470편 이상의 논문이 발표되는 등 연구가 눈에 띄게 진전되고 있으며, 이는 이 분야에 대한 여러 업계 및 학계의 관심이 높아졌음을 보여줍니다. 기술 혁신과 제휴 활동 증가 속도에 힘입어 암 바이오마커 시장은 당분간 꾸준히 성장할 것으로 전망됩니다. 암 바이오마커 시장은 2035년까지 연평균 복합 성장률(CAGR) 5%로 성장할 것으로 예상되며, 2035년까지 북미가 시장의 대부분(45% 이상)을 차지할 것으로 예측됩니다.

세계의 암 바이오마커(Cancer Biomarker) 시장에 대해 조사했으며, 시장 개요와 함께 바이오마커 유형별/암 유형별/주요 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려사항

제4장 주요 요약

제5장 서론

제6장 시장 구도

제7장 제품 경쟁력 분석

제8장 기업 개요

제9장 바이오마커에 근거한 임상시험을 위한 혁신적인 연구 디자인

제10장 임상시험 분석

제11장 출판물 분석

제12장 대형 제약 기업 : 벤치마킹 분석

제13장 사례 연구 : 동반진단 업계 밸류체인 분석

제14장 향후 성장 기회

제15장 세계의 암 바이오마커 시장

제16장 암 바이오마커 시장, 바이오마커 유형별

제17장 암 바이오마커 시장, 암 유형별

제18장 암 바이오마커 시장, 주요 지역별

제19장 결론

제20장 주요 인사이트

제21장 부록 1 : 표 형식 데이터

제22장 부록 2 : 기업 및 단체 리스트

LSH

영문 목차

영문목차

CANCER BIOMARKERS MARKET: OVERVIEW

As per Roots Analysis, the global cancer biomarkers market is estimated to grow from USD 28.6 billion in the current year to USD 46.7 billion by 2035, at a CAGR of 5% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Biomarker

• HER2
• MET
• EGFR
• PD-L1
• NTRK
• ALK
• Novel Biomarkers
• Other Biomarkers

Type of Cancer

• Breast Cancer
• Prostate Cancer
• Colorectum Cancer
• Lung Cancer
• Thyroid Cancer
• Bladder Cancer
• Melanoma
• Non-Hodgkins Lymphoma
• Endometrial Cancer
• Kidney Cancer
• Leukemia

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

CANCER BIOMARKERS MARKET: GROWTH AND TRENDS

The clinical success of several immunotherapies, such as checkpoint inhibitors, has already been established across multiple solid tumors. However, there still exists an unmet need related to evaluating the type of therapy that is to be used for treating different individuals suffering from a specific type of cancer. This is attributed to the fact that patients suffering from same cancer (same stage of the disease) may have exhibited different molecular profiles and respond differently to recommended drug / therapy types. In order to achieve better results for the patients, it is critical to identify reliable cancer biomarkers. Biomarkers provide valuable information about the molecular characteristics of individual tumors, allowing clinicians to tailor treatment strategies to each patient's unique profile.

The future of cancer biomarkers is promising as they have the potential to be used in various aspects of cancer medicine, such as screening, cancer classification, risk assessment, determination of tumor burden, personalization and monitoring of treatment, and prognosis. Moreover, advancements in genomic, proteomic, metabolomic, and microRNomic profiling, along with other techniques, such as comparative genome hybridization (CGH), single nucleotide polymorphism (SNP) analysis, high throughput screening (HTS) and next-generation sequencing (NGS), are paving the way for the discovery of new tumor signatures. Furthermore, the emergence of powerful proteomic and genomic technologies, combined with the analysis of circulating tumor cells (CTC), cancer stem cell-specific markers and cell-free circulating tumor DNA (ctDNA) are contributing to the development of more sensitive and specific biomarkers for early cancer detection, disease progression monitoring and proper treatment selection. Given the ongoing pace of innovation, and increasing interest towards personalized approaches, the cancer biomarkers market is poised to experience a noteworthy growth in the foreseeable future.

CANCER BIOMARKERS MARKET: KEY INSIGHTS

The report delves into the current state of the cancer biomarkers market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• Presently, close to 100 novel cancer biomarker solutions are available in the market; majority of these solutions use next generation sequencing for the assessment of cancer biomarkers.

• Stakeholders in this industry are engaged in providing novel cancer biomarker solutions for a wide range of applications; more than 70% of these solutions assist in the evaluation of MSI / MMR.
• The current market landscape of cancer biomarker testing solution providers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US.
• Close to 685 clinical trials (with more than 75,000 enrolled patients) are currently ongoing in order to investigate novel cancer biomarkers, across different geographies.
• The field of cancer biomarkers has seen a significant rise in research, with over 470 articles published by various researchers, underscoring the growing focus of several industry players and academic players in this domain.
• Driven by the increasing pace of innovation and partnership activity, the market for cancer biomarkers is poised to witness steady growth in the foreseeable future.
• The cancer biomarkers market is anticipated to grow at a CAGR of 5%, till 2035; North America is expected to capture the majority share (over 45%) of the market by 2035.

CANCER BIOMARKERS MARKET: KEY SEGMENTS

HER2 Biomarker Occupies the Largest Share of the Cancer Biomarkers Market

Based on the type of biomarker, the market is segmented into HER2, MET, EGFR, PD-L1, NTRK, ALK, novel biomarkers and other biomarkers. At present, HER2 biomarkers hold the maximum share of the cancer biomarkers market. It is worth highlighting that the cancer biomarkers market for EGFR is likely to grow at a relatively higher CAGR in the near future.

Breast Cancer is Likely to Dominate the Cancer Biomarkers Market During the Forecast Period

Based on the type of cancer, the market is segmented into breast cancer, prostate cancer, colorectum cancer, lung cancer, thyroid cancer, bladder cancer, melanoma, non-Hodgkins's lymphoma, endometrial cancer, kidney cancer and leukemia. Currently, breast cancer holds the maximum share of the cancer biomarkers market. This trend is unlikely to change in the near future.

North America Accounts for the Largest Share of the Market

Based on the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. Majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Cancer Biomarkers Market

• Agilent
• ARUP Laboratories
• BioReference
• Foundation Medicine
• OncoDNA
• Q2 Solutions
• Thermo Fisher Scientific
• YuceBio
• Asper Biogene
• Caris Life Sciences
• CeGaT
• Genekor Medical
• Guardant Health
• Labcorp
• MedGenome
• NeoGenomics Laboratories
• Nonacus
• Oxford Gene Technology
• Personal Genome Diagnostics
• PhenoPath
• Positive Biosciences
• Quest Diagnostics
• Tempus

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Technical Officer and Former Director of Preclinical Development & Strategic Partnerships, Large Company, US
• Business Manager, Mid-sized Company, Germany
• Former Chief Scientific Officer, Large Company, US

CANCER BIOMARKERS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cancer biomarkers market, focusing on key market segments, including [A] type of biomarker, [B] type of cancer and [C] geographical regions.
• Market Landscape: A comprehensive evaluation of testing solutions for novel cancer biomarkers, considering various parameters, such as [A] type of biomarkers, [B] profiling technology used, [C] analytical technique used, [D] turnaround time, [E] sample input, [F] type nucleic acid tested, [G] type of cancer and [H] application area. Additionally, it includes a detailed list of developers engaged in offering novel cancer biomarker testing solutions, along with analysis based on various parameters, such as [I] year of establishment, [J] company size (in terms of employee count) and [K] location of headquarters.
• Product Competitiveness Analysis: A comprehensive competitive analysis of novel cancer biomarker testing solutions, examining factors, such as product versatility and product competitiveness.
• Company Profiles: In-depth profiles of key industry players offering novel cancer biomarker testing solutions, focusing on [A] company overviews, [B] financial information, [C] cancer biomarker testing solutions portfolio, [D] recent developments and [E] an informed future outlook.
• Case Study: A general discussion on the innovative study designs involved in conducting biomarker-based clinical trial to evaluate drugs for oncological disorders. It includes details on the structure of each study design, highlighting their respective advantages and challenges.
• Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various novel cancer biomarkers based on parameters like [A] trial registration year, [B] trial status, [C] trial phase, [D] enrolled patient population, [E] type of sponsor / collaborator, [F] most active players (in terms of number of registered trials), [G] study design, [H] target therapeutic area and [I] key geographical regions.
• Publication Analysis: A detailed publication analysis of over 630 articles that have been published since 2019, highlighting the key focus areas of ongoing research related to novel cancer biomarkers. It highlights the prevalent trends based on the [A] year of publication, [B] type of publication, [C] type of cancer, [D] copyright holders, [E] emerging focus areas, [F] most active publishers (in terms of number of publications) and [G] key journals (in terms of journal impact factor and number of articles published).
• Big Pharma Analysis: A comprehensive examination of various initiatives focused on cancer biomarkers undertaken by major pharmaceutical companies. This analysis includes heat map visualizations that illustrate the distribution of leading pharmaceutical firms, as well as spider web diagrams that compare their initiatives across multiple relevant parameters.
• Case Study: A comprehensive value chain analysis that explores the various stages involved in the production of companion diagnostics. This includes a discussion on research and development (R&D), clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing activities and the cost distribution across each of the aforementioned stages.
• Future Growth Opportunities: A detailed discussion on the upcoming opportunities for cancer biomarker testing solution providers in this field that are likely to impact on the evolution of the market in the short to mid-term and mid to long-term.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What are the factors that are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Research Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Future Estimates
  • 3.2.2. Currency Coverage and Foreign Exchange Rate
    • 3.2.2.1. Major Currencies Affecting the Market
    • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
    • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
    • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
  • 3.2.3. Trade Policies
    • 3.2.3.1. Impact of Trade Barriers on the Market
    • 3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. An Overview of Cancer Biomarkers
  • 5.2.1. Need for Cancer Biomarkers
  • 5.2.2. Identification of a Candidate Biomarker
• 5.3. Type of Cancer Biomarkers
• 5.4. Novel Cancer Biomarkers
  • 5.4.1. Tumor Mutation Burden (TMB)
    • 5.4.1.1. Variation of TMB across Multiple Indications
    • 5.4.1.2. Methods for Measurement of TMB
    • 5.4.1.3. Factors Affecting Measurement of TMB
    • 5.4.1.4. Initiatives for Assessment of TMB as a Potential Biomarker
  • 5.4.2. Microsatellite Instability / Mismatch Repair Deficiency (MSI / MMR)
    • 5.4.2.1. Variation of MSI across Multiple Indications
    • 5.4.2.2. Methods for Measurement of MSI
  • 5.4.3. Single Nucleotide Variants
    • 5.4.3.1. Variation of SNV across Multiple Indications
    • 5.4.3.2. Methods for Measurement of SNV
  • 5.4.4. Copy Number Variants
    • 5.4.4.1. Variation of CNV across Multiple Indications
    • 5.4.4.2. Methods for Measurement of CNV
  • 5.4.5. Tumor Infiltrating Lymphocytes and Other Novel Biomarkers
• 5.5. Future Perspective

6. MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Cancer Biomarker Testing Solutions: Overall Market Landscape
  • 6.2.1. Analysis by Type of Biomarker
  • 6.2.2. Analysis by Profiling Technology Used
  • 6.2.3. Analysis by Analytical Technique Used
  • 6.2.4. Analysis by Turnaround Time
  • 6.2.5. Analysis by Sample Input
  • 6.2.6. Analysis by Type of Nucleic Acid Tested
  • 6.2.7. Analysis by Type of Cancer
  • 6.2.8. Analysis by Application Area
• 6.3. Cancer Biomarkers Testing Solutions: Developer Landscape
  • 6.3.1. Analysis by Year of Establishment
  • 6.3.2. Analysis by Company Size
  • 6.3.3. Analysis by Location of Headquarters

7. PRODUCT COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Assumptions and Key Parameters
• 7.3. Methodology
• 7.4. Cancer Biomarkers Testing Solutions: Product Competitiveness Analysis
  • 7.4.1. Products Offered by Players Based in North America
  • 7.4.2. Products Offered by Players Based in Europe
  • 7.4.3. Products Offered by Players Based in Asia-Pacific

8. COMPANY PROFILES

• 8.1. Chapter Overview
• 8.2. Detailed Profiles of Leading Cancer Biomarker Testing Solutions Providers
  • 8.2.1. Agilent
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Information
    • 8.2.1.3. Cancer Biomarker Testing Solutions Portfolio
    • 8.2.1.4. Recent Developments and Future Outlook
  • 8.2.2. ARUP Laboratories
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.2.2.3. Recent Developments and Future Outlook
  • 8.2.3. BioReference
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.2.3.3. Recent Developments and Future Outlook
  • 8.2.4. Foundation Medicine
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.2.4.3. Recent Developments and Future Outlook
  • 8.2.5. OncoDNA
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.2.5.3. Recent Developments and Future Outlook
  • 8.2.6. Q2 Solutions
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.2.6.3. Recent Developments and Future Outlook
  • 8.2.7. Thermo Fisher Scientific
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Information
    • 8.2.7.3. Cancer Biomarker Testing Solutions Portfolio
    • 8.2.7.4. Recent Developments and Future Outlook
  • 8.2.8. YuceBio
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Cancer Biomarker Testing Solutions Portfolio
    • 8.2.8.3. Recent Developments and Future Outlook
• 8.3. Short Profiles of Other Leading Cancer Biomarkers Testing Solutions Providers
  • 8.3.1. Asper Biogene
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Cancer Biomarker Testing Solutions Portfolio
  • 8.3.2. Caris Life Sciences
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Cancer Biomarkers Testing Solutions Portfolio
  • 8.3.3. CeGaT
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Cancer Biomarkers Testing Solutions Portfolio
  • 8.3.4. Genekor Medical
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Cancer Biomarkers Testing Solutions Portfolio
  • 8.3.5. Guardant Health
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Cancer Biomarker Testing Solutions Portfolio
  • 8.3.6. Labcorp
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Cancer Biomarker Testing Solutions Portfolio
  • 8.3.7. MedGenome
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Cancer Biomarker Testing Solutions Portfolio
  • 8.3.8. NeoGenomics Laboratories
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Cancer Biomarker Testing Solutions Portfolio
  • 8.3.9. Nonacus
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Cancer Biomarkers Testing Solutions Portfolio
  • 8.3.10. Oxford Gene Technology
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Cancer Biomarkers Testing Solutions Portfolio
  • 8.3.11. Personal Genome Diagnostics
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Cancer Biomarkers Testing Solutions Portfolio
  • 8.3.12. PhenoPath
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Cancer Biomarkers Testing Solutions Portfolio
  • 8.3.13. Positive Biosciences
    • 8.3.13.1. Company Overview
    • 8.3.13.2. Cancer Biomarkers Testing Solutions Portfolio
  • 8.3.14. Quest Diagnostics
    • 8.3.14.1. Company Overview
    • 8.3.14.2. Cancer Biomarkers Testing Solutions Portfolio
  • 8.3.15. Tempus
    • 8.3.15.1. Company Overview
    • 8.3.15.2. Cancer Biomarkers Testing Solutions Portfolio

9. INNOVATIVE STUDY DESIGNS FOR BIOMARKER-BASED CLINICAL TRIALS

• 9.1. Chapter Overview
• 9.2. Study Designs for Biomarker-based Clinical Trials
  • 9.2.1. Enrichment Design
  • 9.2.2. All-comers Design
  • 9.2.3. Mixture / Hybrid Design
  • 9.2.4. Adaptive Design
• 9.3. Regulatory Guidelines for Biomarker-based Clinical Trial Designs

10. CLINICAL TRIAL ANALYSIS

• 10.1. Chapter Overview
• 10.2. Scope and Methodology
• 10.3. Cancer Biomarkers: Clinical Trial Analysis
  • 10.3.1. Analysis by Trial Registration Year
  • 10.3.2. Analysis by Trial Status
  • 10.3.3. Analysis by Trial Registration Year and Trial Status
  • 10.3.4. Analysis by Trial Phase
  • 10.3.5. Analysis by Trial Registration Year and Trial Phase
  • 10.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
  • 10.3.7. Analysis of Enrolled Patient Population by Trial Phase
  • 10.3.8. Analysis by Type of Sponsor / Collaborator
  • 10.3.9. Most Active Players: Distribution by Number of Registered Trials
  • 10.3.10. Analysis by Study Design
  • 10.3.11. Analysis by Type of Cancer
  • 10.3.12. Analysis of Clinical Trials by Geography
  • 10.3.13. Analysis of Clinical Trials by Trial Status and Geography
  • 10.3.14. Analysis of Enrolled Patient Population by Geography
  • 10.3.15. Analysis of Enrolled Patient Population by Trial Status and Geography

11. PUBLICATION ANALYSIS

• 11.1. Chapter Overview
• 11.2. Scope and Methodology
• 11.3. Cancer Biomarkers: Publication Analysis
  • 11.3.1. Analysis by Year of Publication
  • 11.3.2. Analysis by Type of Publication
  • 11.3.3. Analysis by Type of Cancer
  • 11.3.4. Analysis by Copyright Holders
  • 11.3.5. Word Cloud: Emerging Focus Areas
  • 11.3.6. Most Active Publishers: Analysis by Number of Publications
  • 11.3.7. Key Journals: Analysis by Number of Publications
  • 11.3.8. Key Journals: Analysis by Impact Factor

12. BIG PHARMA PLAYERS: BENCHMARK ANALYSIS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Big Pharma Players: Benchmarking Analysis
  • 12.3.1. Spider Web Analysis: Abbott
  • 12.3.2. Spider Web Analysis: AbbVie
  • 12.3.3. Spider Web Analysis: Amgen
  • 12.3.4. Spider Web Analysis: AstraZeneca
  • 12.3.5. Spider Web Analysis: Bayer
  • 12.3.6. Spider Web Analysis: Boehringer Ingelheim
  • 12.3.7. Spider Web Analysis: Bristol-Myers Squib
  • 12.3.8. Spider Web Analysis: Eli Lilly
  • 12.3.9. Spider Web Analysis: Gilead
  • 12.3.10. Spider Web Analysis: GlaxoSmithKline
  • 12.3.11. Spider Web Analysis: Merck
  • 12.3.12. Spider Web Analysis: Novartis
  • 12.3.13. Spider Web Analysis: Pfizer
  • 12.3.14. Spider Web Analysis: Roche
  • 12.3.15. Spider Web Analysis: Sanofi
• 12.4. Concluding Remarks

13. CASE STUDY: ANALYSIS OF VALUE CHAIN IN THE COMPANION DIAGNOSTICS INDUSTRY

• 13.1. Chapter Overview
• 13.2. Companion Diagnostics: Value Chain
• 13.3. Cost Distribution Across the Value Chain
  • 13.3.1. Costs Associated with Research and Product Development
  • 13.3.2. Costs Associated with Manufacturing and Assembly
  • 13.3.3. Costs Associated with Clinical Trials, FDA Approval and Other Administrative Tasks
  • 13.3.4. Costs Associated with Payer Negotiation and KOL Engagement
  • 13.3.5. Costs Associated with Marketing and Sales

14. FUTURE GROWTH OPPORTUNITIES

• 14.1. Chapter Overview
• 14.2. Growing Focus on Personalized Medicines
• 14.3. Extent of Biomarker Testing for Various Oncological Disorders
• 14.4. Increase in Number of Biomarker-based Clinical Trials
• 14.5. Increased Adoption of Emerging Analytical Techniques for Biomarker Assessment
• 14.6. Development of Companion Diagnostic Products

15. GLOBAL CANCER BIOMARKERS MARKET

• 15.1. Chapter Overview
• 15.2. Assumptions and Methodology
• 15.3. Global Cancer Biomarkers Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 15.3.1. Scenario Analysis
    • 15.3.1.1. Conservative Scenario
    • 15.3.1.2. Optimistic Scenario
• 15.4. Key Market Segmentations

16. CANCER BIOMARKERS MARKET, BY TYPE OF BIOMARKER

• 16.1. Chapter Overview
• 16.2. Key Assumptions and Methodology
• 16.3. Cancer Biomarkers Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
  • 16.3.1. Cancer Biomarkers Market for HER2 Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 16.3.2. Cancer Biomarkers Market for MET Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 16.3.3. Cancer Biomarkers Market for EGFR Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 16.3.4. Cancer Biomarkers Market for PD-L1 Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 16.3.5. Cancer Biomarkers Market for NTRK Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 16.3.6. Cancer Biomarkers Market for ALK Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 16.3.7. Cancer Biomarkers Market for Other Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 16.3.7.1. Cancer Biomarkers Market: Distribution of Novel Biomarkers, 2018, 2024 and 2035
      • 16.3.7.1.1. Cancer Biomarkers Market for SNV Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
      • 16.3.7.1.2. Cancer Biomarkers Market for MSI Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
      • 16.3.7.1.3. Cancer Biomarkers Market for CNV Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
      • 16.3.7.1.4. Cancer Biomarkers Market for TMB Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
      • 16.3.7.1.5. Cancer Biomarkers Market for TIL Biomarkers: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 16.4. Data Triangulation and Validation

17. CANCER BIOMARKERS MARKET, BY TYPE OF CANCER

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Cancer Biomarkers Market: Distribution by Type of Cancer, 2018, 2024 and 2035
  • 17.3.1. Cancer Biomarkers Market for Breast Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.2. Cancer Biomarkers Market for Prostate Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.3. Cancer Biomarkers Market for Colorectum Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.4. Cancer Biomarkers Market for Lung Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.5. Cancer Biomarkers Market for Thyroid Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.6. Cancer Biomarkers Market for Bladder Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.7. Cancer Biomarkers Market for Melanoma: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.8. Cancer Biomarkers Market for Non-Hodgkin Lymphoma: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.9. Cancer Biomarkers Market for Endometrial Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.10. Cancer Biomarkers Market for Kidney Cancer: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 17.3.11. Cancer Biomarkers Market for Leukemia: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 17.4. Data Triangulation and Validation

18. CANCER BIOMARKERS MARKET, BY KEY GEOGRAPHICAL REGIONS

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Cancer Biomarkers Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
  • 18.3.1. Cancer Biomarkers Market in North America: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.1.1. Cancer Biomarkers Market in the US: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.1.2. Cancer Biomarkers Market in Canada: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.2. Cancer Biomarkers Market in Europe: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.2.1. Cancer Biomarkers Market in the UK: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.2.2. Cancer Biomarkers Market in Germany: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.2.3. Cancer Biomarkers Market in France: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.2.4. Cancer Biomarkers Market in Spain: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.2.5. Cancer Biomarkers Market in Italy: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.3. Cancer Biomarkers Market in Aisa-Pacific: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.3.1. Cancer Biomarkers Market in China: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.3.2. Cancer Biomarkers Market in Japan: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.3.3. Cancer Biomarkers Market in India: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.3.4. Cancer Biomarkers Market in Australia: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.3.5. Cancer Biomarkers Market in South Korea: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.3.6. Cancer Biomarkers Market in New Zealand: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
  • 18.3.4. Cancer Biomarkers Market in Rest of the World: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.4.1. Cancer Biomarkers Market in Brazil: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.4.2. Cancer Biomarkers Market in Argentina: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.4.3. Cancer Biomarkers Market in Chile: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
    • 18.3.4.4. Cancer Biomarkers Market in Egypt: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
• 18.4. Data Triangulation and Validation

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS

• 20.1. Chapter Overview
• 20.2. Cell IDc
  • 20.2.1. Company Snapshot
  • 20.2.2. Interview Transcript: David Schwartz, Chief Technical Officer and Helen Synder, Former Director of Preclinical Development & Strategic Partnerships
• 20.3. CeGat
  • 20.2.1. Company Snapshot
  • 20.2.2. Interview Transcript: Kirill Shur, Business Manager
• 20.4. NeoGenomics Laboratories
  • 20.2.1. Company Snapshot
  • 20.2.2. Interview Transcript: Lawrence Weiss, Former Chief Scientific Officer

21. APPENDIX 1: TABULATED DATA

22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료